Treatment of cytomegalovirus retinitis with the intraocular ganciclovir implant

Current Opinion in Ophthalmology

Volumn 8, Issue 3, 1997, Pages 8-14

  Anand, Rajiv ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; FOSCARNET; GANCICLOVIR;

BONE MARROW SUPPRESSION; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DRUG COATING; DRUG EFFICACY; DRUG HALF LIFE; DRUG IMPLANT; DRUG USE; HUMAN; INTRAOCULAR DRUG ADMINISTRATION; INTRAVITREAL DRUG ADMINISTRATION; NEPHROTOXICITY; NONHUMAN; PATIENT CARE; PRIORITY JOURNAL; RETINITIS; REVIEW; SURGICAL TECHNIQUE; SUSTAINED RELEASE FORMULATION;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS RETINITIS; DRUG IMPLANTS; GANCICLOVIR; HUMANS; TREATMENT OUTCOME;

EID: 0030762079     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-199706000-00003     Document Type: Review

References (24)

1. Freeman WR, Lerner CW, Mines JA, Lash RS, Nadel AJ, Starr MB, Tapper ML.: A prospective study of ophthalmologic findings in the acquired immune deficiency syndrome. Am J Ophthalmol 1984, 97:133-142.
2. Jabs DA, Enger C, Bartlett JG: Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol 1989, 107:75-80.
3. Holland GN: Acquired immunodeficiency syndrome and ophthalmology: the first decade. Am J Ophthalmol 1992, 114:86-95.
4. Jabs DA: Acquired immune deficiency and the eye-1996 [editorial]. Arch Ophthalmol 1996, 114:863-866.
5. Hoover DR, Yun P, Saah AJ, Semba R, Detels RR, Rinaldo CR, Phair JP: • Occurrence of Cytomegalovirus retinitis after human immunodeficiency virus immunosupression. Arch Ophthalmol 1996, 114:821-827. The importance of recognizing population at risk for developing CMV-R with decreasing immunity is discussed.
6. Kupperman BD, Petty JG, Richman DD. et al.: Correlation between • CD4+ counts and prevalence of Cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am J Ophthalmol 1993, 115:575-582. Important correlation established between the state of the immune system and the prevalence of opportunistic infections.
7. SOCA & ACTG Group: Combination foscarnet and ganciclovir versus monotherapy for Cytomegalovirus retinitis in AIDS. Arch Ophthalmol 1996, 114:23-33.
8. Roarty JD, Fisher EJ, Nussbaum JJ: Long-term visual morbidity of Cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophthalmology 1993, 100:1686-1688.
9. Kupperman BD, Quiceno JI, Flores-Aguilar M: Intravitreal ganciclovir concentration after intravenous administration in AIDS patients with Cytomegalovirus retinitis: implications for therapy. J Infect Dis 1993, 168:1506-1509.
10. Anand R, Font RL, Fish RH, Nightingale SD: Pathology of Cytomegalovirus retinitis treated with sustained-release intravitreal ganciclovir. Ophthalmology 1993, 100:1032-1039.
11. Cantrill HL, Henry K, Melroe NH: Treatement of Cytomegalovirus retinitis with intravitreal ganciclovir: long-term results. Ophthalmology 1989, 96:376-374.
12. Smith TJ, Pearson PA, Blandfird DL, et al.: Intravitreal sustained-release ganciclovir. Arch Ophthalmol 1992, 110:255-258.
13. Sanborn GE, Anand R, Torti RE, et al.: Sustained-release ganciclovir •• therapy for treatment of Cytomegalovirus retinitis: use of an intravitreal device. Arch Ophthalmol 1992, 110:188-195. This report describes the surgical technique and the first successful results of the implant.
14. Anand R, Nightingale SD, Fish RH, Smith TJ, Ashton P: Control of Cy•• tomegalovirus retinitis using sustained release of intraocular ganciclovir. Arch Ophthalmol 1993, 111:223-227. This article reports on the prospective analysis of the initial study of patients who received initial therapy with the implant, as well as salvage therapy. The results are very similar to those of later prospective, controlled study reports.
15. Martin DF, Parks DJ, Mellow SD, et al.: Treatment of Cytomegalovirus • retinitis with an intraocular sustained-release ganciclovir implant Arch Ophthalmol 1994, 112:1531-1539.
16. Morlet N: High-dose intravitreal ganciclovir injection provides a prolonged therapeutic concentration. Br J Ophthalmol 199x, 80:214-216. Controlled study in newly diagnosed CMV-R shows the effect of the device compared with untreated disease.
17. Chiron Vision: Vitrasert™ Product Monograph. Claremont, CA: Chiron •• Vision, 1996. This monograph summarizes the results of the clinical trials. These data were presented to the Food & Drug Administration and at the ICAAC meeting in September 1995.
18. Burd EM, Pulido JS, Puro DG, O'Brien WJ: Maintainence of replicative intermediates in ganciclovir-treated human cytomegalovirus-affected retinal glia. Arch Ophthalmol 1996, 114:856-861.
19. Jabs DA: Cytomegalovirus retinitis and viral resistance. Arch Ophthalmol 1996, 114:809-814.
20. Jabs DA, Enger C, Haller J, et al.: Retinal detachments in patients with cytomegalovirus retinitis. Arch Ophthalmol 1991, 109:794-799.
21. Davis JL, Serfass MS, Lai MY, et al.: Silicone oil in repair of retinal detrachments caused by necrotizing retinitis in HIV infection. Ophthalmology 1995, 113:1401-1409.
22. Lim JI, Enger C, Haller JA, Campochiaro PA, Meredith TA: Improved visual results after surgical repair of cytomegalovirus-related retinal detachments. Ophthalmology 1994, 101:264-269.
23. Duker JS, Ashton PA, Davis JL, et al.: Long-term successful maintainence of bilateral cytomegalovirus retinitis using exclusively local therapy. Arch Ophthalmol 1996, 114:881-882.
24. Marx JL, Kapusta MA, Patel SS: Use of ganciclovir implant in treatment of recurrent cytomegalovirus retinitis. Arch Ophthalmol 1996, 114:815-820.